cilostazol has been researched along with Body Weight in 19 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 7.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "Body weight and abdominal fat was increased in OLETF rats but cilostazol supplementation did not alter them." | 7.70 | Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. ( Harada, N; Minami, A; Nakamura, T; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 1999) |
| "This study evaluated the possible protective effects of cilostazol against myonecrosis in dystrophic diaphragm muscle in vivo, focusing on oxidative stress, the inflammatory response and angiogenesis." | 3.83 | Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle. ( Cagnon, VH; de Faria, FM; Fogaça, AR; Hermes, Tde A; Kido, LA; Macedo, AB; Minatel, E; Moraes, LH, 2016) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 3.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "Body weight and abdominal fat was increased in OLETF rats but cilostazol supplementation did not alter them." | 3.70 | Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. ( Harada, N; Minami, A; Nakamura, T; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 1999) |
| "We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects." | 2.77 | Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects. ( Chang, MJ; Choi, CA; Choi, HD; Kim, SH; Lee, HJ; Lee, SH; Shin, WG, 2012) |
| "Cilostazol treatment may be useful for the management of diabetic retinal vascular dysfunction and neuronal degeneration." | 1.39 | Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. ( Jung, KI; Kim, JH; Park, CK; Park, HY, 2013) |
| "We previously reported that human squamous cell carcinoma (SCC) cell lines refractory to cis-diaminedichloro-platinum II (cisplatin [CDDP]) had significant upregulation of the phosphodiesterase 3B gene (PDE3B), suggesting that inhibiting PDE3B suppresses CDDP resistance." | 1.39 | Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells. ( Baba, T; Iyoda, M; Kasamatsu, A; Ogawara, K; Saito, Y; Sakamoto, Y; Sakuma, K; Shiiba, M; Tanzawa, H; Usukura, K; Uzawa, K, 2013) |
| "Treatment with curcumin in control rats increased the sensitivity to cilostazol." | 1.38 | Curcumin increases vasodilatory effect of cilostazol in diabetic rat aorta. ( Belviranli, M; Gökbel, H; Nurullahoğlu-Atalik, KE; Okudan, N; Simşek, L, 2012) |
| "Cilostazol was reported to lower the production of superoxide significantly in situ." | 1.36 | Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB. ( Chen, CC; Chen, HC; Lee, HJ; Lee, WC; Lin, PY; Ou, TT; Wang, CY; Wang, J; Wen, MC, 2010) |
| "Cilostazol was given to group 2 orally on days 28-90." | 1.35 | Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. ( Chang, LT; Chiang, CH; Lee, FY; Sheu, JJ; Sun, CK; Wu, CJ; Yip, HK; Youssef, AA, 2008) |
| "Cilostazol treatment (30 mg/kg/day p." | 1.29 | Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+ -K+ -ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes. ( Furuta, M; Kishi, Y; Mukoyama, M; Naka, K; Nanjo, K; Sanke, T; Sasaki, H, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, KI | 1 |
| Kim, JH | 1 |
| Park, HY | 1 |
| Park, CK | 1 |
| Uzawa, K | 1 |
| Kasamatsu, A | 1 |
| Baba, T | 1 |
| Usukura, K | 1 |
| Saito, Y | 1 |
| Sakuma, K | 1 |
| Iyoda, M | 1 |
| Sakamoto, Y | 1 |
| Ogawara, K | 1 |
| Shiiba, M | 1 |
| Tanzawa, H | 1 |
| Kumar, A | 2 |
| Jaggi, AS | 1 |
| Singh, N | 1 |
| Hermes, Tde A | 1 |
| Macedo, AB | 1 |
| Fogaça, AR | 1 |
| Moraes, LH | 1 |
| de Faria, FM | 1 |
| Kido, LA | 1 |
| Cagnon, VH | 1 |
| Minatel, E | 1 |
| Park, SY | 1 |
| Shin, HK | 1 |
| Lee, JH | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Hong, KW | 1 |
| Lee, WC | 1 |
| Chen, HC | 1 |
| Wang, CY | 1 |
| Lin, PY | 1 |
| Ou, TT | 1 |
| Chen, CC | 1 |
| Wen, MC | 1 |
| Wang, J | 1 |
| Lee, HJ | 2 |
| Takeda, M | 1 |
| Yamashita, T | 1 |
| Shinohara, M | 1 |
| Sasaki, N | 1 |
| Tawa, H | 1 |
| Nakajima, K | 1 |
| Momose, A | 1 |
| Hirata, K | 1 |
| Choi, HD | 1 |
| Lee, SH | 1 |
| Kim, SH | 1 |
| Choi, CA | 1 |
| Chang, MJ | 1 |
| Shin, WG | 1 |
| Nurullahoğlu-Atalik, KE | 1 |
| Okudan, N | 1 |
| Belviranli, M | 1 |
| Gökbel, H | 1 |
| Simşek, L | 1 |
| Nakai, K | 1 |
| Takenobu, Y | 1 |
| Takimizu, H | 1 |
| Akimaru, S | 1 |
| Maegawa, H | 1 |
| Ito, H | 1 |
| Marsala, M | 1 |
| Katsube, N | 1 |
| Manickavasagam, S | 1 |
| Ye, Y | 1 |
| Lin, Y | 1 |
| Perez-Polo, RJ | 1 |
| Huang, MH | 1 |
| Lui, CY | 1 |
| Hughes, MG | 1 |
| McAdoo, DJ | 1 |
| Uretsky, BF | 1 |
| Birnbaum, Y | 1 |
| Chang, LT | 1 |
| Sun, CK | 1 |
| Sheu, JJ | 1 |
| Chiang, CH | 1 |
| Youssef, AA | 1 |
| Lee, FY | 1 |
| Wu, CJ | 1 |
| Yip, HK | 1 |
| Kihara, M | 1 |
| Schmelzer, JD | 1 |
| Low, PA | 1 |
| Naka, K | 1 |
| Sasaki, H | 2 |
| Kishi, Y | 1 |
| Furuta, M | 1 |
| Sanke, T | 1 |
| Nanjo, K | 1 |
| Mukoyama, M | 1 |
| Hotta, N | 2 |
| Koh, N | 2 |
| Sakakibara, F | 2 |
| Nakamura, J | 2 |
| Hamada, Y | 2 |
| Hara, T | 2 |
| Mori, K | 2 |
| Naruse, K | 1 |
| Fukasawa, H | 1 |
| Kakuta, H | 1 |
| Sakamoto, N | 1 |
| Nakashima, E | 1 |
| Kasama, N | 1 |
| Inukai, S | 1 |
| Yamamoto, Y | 2 |
| Yasuda, Y | 2 |
| Kimura, Y | 1 |
| Komiya, Y | 2 |
| Nakaya, Y | 1 |
| Minami, A | 1 |
| Sakamoto, S | 1 |
| Niwa, Y | 1 |
| Ohnaka, M | 1 |
| Harada, N | 1 |
| Nakamura, T | 1 |
1 trial available for cilostazol and Body Weight
| Article | Year |
|---|---|
Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects.
Topics: Adult; Age Factors; Asian People; Body Weight; Cilostazol; Cross-Over Studies; Humans; Male; Platele | 2012 |
18 other studies available for cilostazol and Body Weight
| Article | Year |
|---|---|
Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats.
Topics: Animals; Apoptosis; Blood Glucose; Blotting, Western; Body Weight; Cell Death; Cilostazol; Diabetic | 2013 |
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carcinoma, Squamous | 2013 |
Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia.
Topics: Animals; Blood Glucose; Body Weight; Brain Chemistry; Cilostazol; Dementia, Vascular; Diabetes Melli | 2015 |
Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle.
Topics: Animals; Body Weight; Cilostazol; Creatine Kinase; Diaphragm; Female; Male; Mice; Mice, Inbred mdx; | 2016 |
Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Animals; Biomarkers; Blood Glucose; Body Weight; Cilostaz | 2009 |
Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB.
Topics: Animals; Blood Glucose; Body Weight; Cilostazol; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nep | 2010 |
Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Brachiocephalic Trunk; Cell Adhesio | 2012 |
Curcumin increases vasodilatory effect of cilostazol in diabetic rat aorta.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Cilostazol; Curcumin; Diabetes Mellitus, Exper | 2012 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent C | 2003 |
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
Topics: Adenosine; Administration, Oral; Animals; Atorvastatin; Body Weight; Cilostazol; Cyclic AMP-Dependen | 2007 |
Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model.
Topics: Animals; Blood Pressure; Body Weight; Cilostazol; Connexin 43; Disease Models, Animal; Endothelium, | 2008 |
Effect of cilostazol on experimental diabetic neuropathy in the rat.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cilostazol; Diabetes Mellitus, Experimental; Di | 1995 |
Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+ -K+ -ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Body Weight; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; Diabet | 1995 |
Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose feeding: effect of an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Alcohols; Animals; Anticoagulants; Blood Glucose; Body Weight; Carbohydrate | 1996 |
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Anticoagulants; Blood Glucose; Body Weight; Cil | 1997 |
Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats.
Topics: Animals; Axons; Blood Glucose; Body Weight; Cilostazol; Diabetes Mellitus, Experimental; Diabetic Ne | 1998 |
Cilostazol prevents impairment of slow axonal transport in streptozotocin-diabetic rats.
Topics: Animals; Axonal Transport; Blood Glucose; Body Weight; Cilostazol; Cytoskeletal Proteins; Diabetes M | 2000 |
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Topics: Abdomen; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cilostazol; Diabetes Mellitus, Type 2; | 1999 |